References
- Iguchi H, Kato K, Ibayashi Y, Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 1982;5:27–9
- Bellipanni G, Bianchi P, Pierpaoli W, et al. Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study. Exp Gerontol 2001;36:297–310
- Bellipanni G, Di Marzo F, Di Blasi F, Di Marzo A. Effects of melatonin in perimenopausal and menopausal women. Ann NY Acad Sci 2005;1057:393–402
- Unfer V, Carlomagno G, Dante G, Facchinetti F. Effect of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol 2012;28:509–15
- Santamaria A, Giordano D, Corrado F, et al. One-year effect of myo-inositol supplementation in postmenopausal women with metabolic syndrome. Climacteric 2012;15:490–5
- Reusch JE, Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am J Cardiol 2002;9:19G–26
- Park HT, Cho GJ, Ahn KH, et al. Thyroid stimulating hormone is associated with metabolic syndrome in euthyroid postmenopausal women. Maturitas 2009;62:301–5
- Uzunlulu M, Yorulmaz E, Oguz A. Prevalence of subclinical hypothyroidism in patients with metabolic syndrome. Endocrine J 2007;54:71–6
- Shantha GP, Kumar AA, Jeyachandran V, et al. Association between primary hypothyroidism and metabolic syndrome and the role of C-reactive protein: a cross-sectional study from South India. Thyroid Res 2009;2:2
- Giandalia A, Russo GT, Romeo EL, et al. Influence of high-normal serum TSH levels on major cardiovascular risk factors and visceral adiposity index in euthyroid type 2 diabetic subjects. Endocrine 2014;47:152–60
- Fiore E, Vitti P. Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab 2012;97:1134–45
- Bojar I, Owoc A, Gujski M, et al. Functional status of thyroid and cognitive functions after menopause. Med Sci Monit 2015;21:1625–33